Navigation Links
Mayo Clinic researchers find that protein believed to protect against cancer has a Mr. Hyde side
Date:9/3/2009

JACKSONVILLE, Fla. In a biological rendition of fiction's Strange Case of Dr. Jekyll and Mr. Hyde, researchers from the Mayo Clinic campus in Florida and Harvard Medical School have found that a protein thought to protect against cancer development can actually spur the spread of tumors.

The scientists, reporting in the Sept. 3 issue of Molecular and Cellular Biology, found that FOXO3a, a transcription factor that regulates gene expression, becomes active when growing cancer cells begin to starve. Their research suggests that this protein then turns on molecular switches that allow the cancer cells to invade surrounding tissues.

"This is a complete reversal of what everyone thought about FOXO3a that we should find a way to activate this transcription factor so as to fight cancer growth," says cancer biologist Peter Storz, Ph.D., the study's lead investigator from Mayo Clinic in Florida.

Findings from the study, which was funded in part by the Florida Department of Health, illustrate the growing recognition in the research community that proteins can play multiple roles with respect to tumor progression, he says.

"More and more we see that, when it comes to cancer, proteins can have split personalities," Dr. Storz says. "Proteins once firmly believed to be tumor suppressors that protect against cancer development have recently been found to act as oncogenes, or cancer promoters, in certain cancers and in some biological circumstances. We now understand that proteins behave in different ways, depending on the cellular context."

Dr. Storz and his laboratory colleagues focus on understanding how cancer cells spread. This study builds upon a recent finding by collaborating author Alex Toker, Ph.D., associate professor, Department of Pathology, Harvard Medical School. Dr. Toker had found that Akt, a protein that protects tumor cells from programmed cell death and induces proliferation of cancer, in some circums
'/>"/>

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-2299
Mayo Clinic
Source:Eurekalert

Page: 1 2

Related biology news :

1. General tumor marker test now offered by GenWay clinical laboratory
2. Neurimmune Therapeutics Announces Advancement of Alzheimers Program into Preclinical Development
3. Antibody targeting of glioblastoma shows promise in preclinical tests, say Lombardi researchers
4. $20 million NIH grant to transform clinical research at UIC
5. Systems biology recommended as a clinical approach to cancer
6. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
7. Clinical trial shows quadriplegics can operate powered wheelchair with tongue drive system
8. Versartis presents positive preclinical data on 2 product candidates at ENDO 09
9. Brain-computer interface, developed at Brown, begins new clinical trial
10. REGiMMUNE presents enhanced efficacy data in preclinical transplantation models
11. SNMs clinical trials network gains added support from industry leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/20/2015)... , April 20, 2015 Huntington Memorial Hospital ... to implant a new miniaturized, wireless monitoring sensor to ... the first and only FDA-approved heart failure monitoring device ... when used by physicians to manage heart failure. ... is implanted in the pulmonary artery (PA) during a ...
Breaking Biology News(10 mins):Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3
... have found that the main source of food for many ... to adapt in order to survive climate change. Billions ... just a few millimetres in size, live in the waters ... It showed they responded to global warming after the ...
... Enhanced Recognition Capabilities for Use in ... and Computer Vision Applications, VILNIUS, ... ), a provider of high-precision biometric,and ... availability of,SentiSight 2.0 SDK universal object ...
... First Such Board on the Market, Stantum,s SMK ... Their Own Resistive Multi-Touch Applications, SAN DIEGO, ... pioneer developer of multi-touch sensing,technology, today introduced a ... PMatrix(TM) resistive multi-touch technology, which lets,users simultaneously move ...
Cached Biology News:Researchers find animal with ability to survive climate change 2Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology 2Neurotechnology Releases SentiSight 2.0 SDK Universal Object Recognition Technology 3Stantum Offering Demo, Evaluation & Development Board Based on Its Patented Resistive Multi-Touch Technology 2
(Date:5/28/2015)... (PRWEB) May 28, 2015 DryLet, ... use in applications such as animal waste reduction, ... oil reduction in wastewater treatment plants and restaurant ... the World Pork Expo, June 3-5 in Des ... year in a Wall Street Journal article because ...
(Date:5/28/2015)... N.J. , May 28, 2015  PDS ... a cancer immunotherapy treatment targeting HPV-16, has generated ... Currently, pre-cervical cancer is treated by ... a simple and effective non-surgical alternative. Results show ... mechanisms (T-cells) to recognize, target, and kill precancerous ...
(Date:5/28/2015)... 2015 Biscayne Pharmaceuticals, Inc ., today ... growth hormone-releasing hormone (GHRH) technology will be discussed in a ... Meeting. The data show that the family of receptors ... is present on many primary breast cancer cells regardless ... antagonists could have broad anti-cancer potential in breast cancer. ...
(Date:5/28/2015)... and London (PRWEB) May 28, 2015 ... of Computer Aided Engineering software, announced today it ... Inc. (PSRI). CD-adapco will provide state-of-the-art engineering simulation ... will share their expertise and experiences in analyzing ... refining industry members and advance the understanding of ...
Breaking Biology Technology:DryLet to Showcase Patented ManureMagicâ„¢ at the 2015 World Pork Expo, June 3-5 in Des Moines, Iowa 2PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2
... Ill., July 1 Healthation, a healthcare,technology ... large Canadian Third,Party Administrator (TPA) to a ... use,the integrated real-time, rules-based AcceleHealth(R) benefits and ... deliver interactive,self-service capabilities across its medical, dental, ...
... Mich., July 1 Neogen Corporation,(Nasdaq: NEOG ... product line used in,animal health and hygiene applications ... includes 14 different product formulations,along with manufacturing process ... terms were not disclosed., The addition of ...
... BioMarin,Pharmaceutical Inc. (Nasdaq and SWX: BMRN) announced today that ... present a,company update at the Collins Stewart Growth Conference ... 9:30 a.m. ET., Interested parties may access a ... of the BioMarin website, http://www.BMRN.com . A,replay of ...
Cached Biology Technology:Healthation Chosen by Large Canadian Third Party Administrator to Support All Employee Benefits and Claims Administration 2Neogen Acquires Product Line From DuPont Animal Health Solutions 2BioMarin to Present at the Collins Stewart Growth Conference 2
Leucine-rich repeat-containing G-protein coupled receptor 4...
WD-repeat protein 4...
Rabbit polyclonal to MDM2 (phospho S185) ( Abpromise for all tested applications). entrezGeneID: 4193 SwissProtID: Q00987...
... Cultured human omental preadipocytes ... but otherwise healthy donors. ... of diabetic cells. Please ... Support media also available. ...
Biology Products: